THCV vs THC
- THCV
- Dose-dependent CB1 behavior reported Emerging; TRP-channel activity in vitro Demonstrated (De Petrocellis 2011); appetite and metabolic benefits in people not established — catalogue in progress No primary evidence
- THC
- Intoxication through CB1 Established; known to affect heart rate and blood pressure Established; specific therapeutic claims depend on jurisdiction and fall outside this comparison
From the evidence status row of the table below.
THC (delta-9-tetrahydrocannabinol) is the main intoxicating cannabinoid, and it produces a high by activating the CB1 receptor. THCV (tetrahydrocannabivarin), its propyl analog, is marketed almost as THC's mirror image: the cannabinoid that curbs appetite instead of stoking it. Both halves of that pitch wobble. THCV's psychoactivity is dose-dependent, reported non-intoxicating at low doses and possibly intoxicating at higher ones, and its appetite effect has not been established in people; its effects in people are largely unstudied. Established / Emerging
Whose claims are whose. Chemical identity, structure and intoxication status are verified science and carry an evidence grade. Claims about effects or benefits (appetite, weight, energy, metabolic "support") come from others and are reported as their claims; CBG Atlas does not make, adopt or affirm them. Where verified evidence runs out, the entry reads "catalogue in progress." Grades: the six-rung evidence ladder. Not medical, legal, or professional advice.
At a glance
| THCV | THC | |
|---|---|---|
| Full name | THCVTetrahydrocannabivarin | THC(delta-9-)Tetrahydrocannabinol |
| Formula / CAS | THCVC₁₉H₂₆O₂ · CAS 31262-37-0 · CID 93147 · MW ≈286.41 | THCC₂₁H₃₀O₂ · CAS 1972-08-3 · MW ≈314.46 |
| Intoxicating? | THCVDepends on dose: reported non-intoxicating at low doses, possibly intoxicating at higher ones Emerging | THCYes, through CB1 activation Established |
| General legal status (2026; not legal advice) | THCVHemp-derived THCV falls under the 2018 Farm Bill's ≤0.3% delta-9 THC line and under "total-THC" rules that are still changing; varies by state; other countries set their own rules | THCDelta-9 THC above 0.3% by dry weight is federally controlled in the US; many states run medical or adult-use programs; varies by state |
| Commonly marketed for (attributed) | THCVMarketed for appetite suppression ("diet weed"), energy and metabolic "support" (third-party claims) | THCIn legal markets, associated with stimulating appetite ("munchies") and with recreational or medical use (varies by jurisdiction) |
| Evidence status (graded) | THCVDose-dependent CB1 behavior reported Emerging; TRP-channel activity in vitro Demonstrated (De Petrocellis 2011); appetite and metabolic benefits in people not established — catalogue in progress No primary evidence | THCIntoxication through CB1 Established; known to affect heart rate and blood pressure Established; specific therapeutic claims depend on jurisdiction and fall outside this comparison |
The six rungs, and the words each one permits
- grade: Established
- Settled science — replicated human data, or biochemistry that is not in dispute. “is shown to”
- grade: Demonstrated
- Shown reproducibly in controlled experiments — typically laboratory (in-vitro) work. “has been shown to”
- grade: Emerging
- An early signal — preclinical (animal) work, or human evidence too limited to settle the question. “may · early evidence suggests”
- grade: Low
- Limited and low-confidence — sparse, indirect, or single-source data. “limited evidence · unclear”
- grade: Hypothesized
- Proposed and plausible — but not yet shown. “proposed mechanism”
- grade: Not supported
- Tested, and the evidence does NOT support it. This is a finding against the claim — not an absence of evidence. “evidence does not support”
- Catalogue in progress
- Not a rung: our registry holds nothing graded on the question yet. Absence is not evidence against.
A grade rates the support for a claim across the literature, never a single study. How we grade evidence.
- How to read a cell
- An oxblood ring holds the direction: a bar: blocks; a chevron: activates; a chevron with a bar: activates, then desensitises; two bars: damps activation. A gold ring with a dot: recorded in a review, direction qualified by the source, no rung of its own. A dashed frame: no graded interaction in our registry.
- CB1 cannabinoid receptor
- THCV: blocks, and at higher doses activates (direction reverses with dose), in a review, no rung of its own study type: Review Pertwee 2008. THC: activates (partial agonist), in a review, no rung of its own study type: Review Pertwee 2008.
- CB2 cannabinoid receptor
- THCV: activates (partial agonist; an earlier paper reports the opposite), in a review, no rung of its own study type: Review Pertwee 2008. THC: activates (partial agonist), in a review, no rung of its own study type: Review Pertwee 2008.
- α2-adrenoceptor
- THCV: no graded interaction in our registry. THC: no graded interaction in our registry.
- 5-HT1A serotonin receptor
- THCV: no graded interaction in our registry. THC: no graded interaction in our registry.
- TRPV1 and TRPV2 ion channels
- THCV: no graded interaction in our registry. THC: no graded interaction in our registry.
- TRPM8 ion channel
- THCV: no graded interaction in our registry. THC: no graded interaction in our registry.
What the evidence supports
Two questions do most of the work for anyone buying or formulating THCV: will it get me high, and will it curb my appetite? The first has an answer shaped by dose. The second has an answer the marketing would rather skip: the appetite and metabolic benefits THCV is sold on have not been established in people. A third, whether it will trip a drug test, is the one people forget to ask.
- Intoxication is the main difference. THC intoxicates by activating CB1. Established With THCV, the dose decides. It is reported to block the CB1 receptor at low doses, which is why it can be non-intoxicating there, and it may start to activate the receptor at higher doses, so a THCV product marketed as non-intoxicating at every strength is claiming more than the evidence shows. Emerging (targets stated in words only; no potency figures)
- Verified lab activity (THCV). Beyond CB1, THCV acts on TRP channels in vitro (De Petrocellis 2011), a cell-level finding rather than a demonstrated effect in people. Demonstrated
- Structure. The family resemblance is real and small. THCV is THC's propyl analog, a "varin" with a three-carbon side chain where THC has a five-carbon (pentyl) one, built by the plant along the varin branch, CBGVA → THCVA → THCV, with the acid shedding CO₂ when heated. Established
- Appetite: attributed, not affirmed. Here the marketing turns THC's best-known side effect inside out. THC is widely linked to increased appetite (the "munchies") through CB1, and THCV is sold for the reverse, appetite suppression. Early animal research has looked at this, yet the effect is not established in humans, THCV holds no approval as a weight-loss product, and an appetite or weight claim on a THCV label has no human trial behind it. Emerging (preclinical) / No primary evidence (human — our registry holds no human trial either way)
- Drug testing: either can trip a test. Standard tests are built to detect THC and its metabolites, so THC use can produce a positive. Established THCV gets in by the side door: tests target THC rather than THCV, yet many THCV products carry trace THC that tests pick up, and related cannabinoids may cross-react. How THCV itself behaves on a test is still poorly characterized (catalogue in progress). Anyone who is drug-tested is safest avoiding both. Established (trace-THC risk) / No primary evidence (THCV-specific test behaviour — catalogue in progress)
- Cardiovascular: read this if blood pressure is a concern. THC is known to affect heart rate and blood pressure. Established More broadly, some cannabinoids — notably CBG — act at the α2-adrenoceptor (Cascio 2010), a target linked to blood-pressure regulation. How THCV affects the heart and circulation is still poorly mapped. Anyone with blood-pressure concerns or on cardiovascular medication should consult a clinician before using any cannabinoid product.
- Safety & dosing. No human dose of THCV has been established, and data on its safety and drug interactions are thin (catalogue in progress). This page gives no dosing guidance.
Common questions
Does THCV get you high like THC?
Not the way THC does, and how close it comes depends on the dose. THC is strongly intoxicating because it switches on the CB1 receptor. THCV is reported to block that receptor at low doses, where it tends to be non-intoxicating, and it may start switching it on at higher doses. So how intoxicating a THCV product is depends on how much it delivers. Emerging
Is THCV "diet weed" — does it suppress appetite?
It's the marketing claim, and it remains unproven. The nickname comes from a neat reversal: proponents and early animal research suggest THCV may suppress appetite, the opposite of THC's familiar "munchies." The human side of the ledger is blank, since our registry holds no human trial of THCV's effect on appetite in either direction, so the effect is not established, and THCV holds no approval as a weight-loss product. Read that as a gap in the record rather than a finding against it. No primary evidence · catalogue in progress (Not medical advice.)
Will THCV or THC show up on a drug test?
THC almost certainly can, because standard tests are built to detect THC and its metabolites. THCV is the less direct risk: tests look for THC rather than THCV, but many THCV products carry trace THC that tests detect, and related cannabinoids may cross-react. THCV's own behavior on a test is still poorly characterized (catalogue in progress), so anyone who is drug-tested is safest avoiding both. Established (for THC / trace-THC risk)
What's the structural difference between THCV and THC?
The length of the side chain. THC (C₂₁H₃₀O₂) carries a five-carbon pentyl chain; THCV (C₁₉H₂₆O₂) carries a shorter three-carbon propyl chain, and those two missing carbons are what make it a "varin." The plant makes THCV along its varin branch, where CBGVA becomes THCVA and the acid group falls away with heat to leave THCV. Established
Are THCV and THC legal?
It depends on the compound, the jurisdiction and the date. As of 2026, delta-9 THC above 0.3% by dry weight is federally controlled in the US, although many states run medical or adult-use programs. Hemp-derived THCV rides on the 2018 Farm Bill's 0.3% delta-9 line and on "total-THC" rules that are still changing, and states differ. General information, not legal advice. Established
Does THCV or THC affect blood pressure or the heart?
THC does: it is known to affect heart rate and blood pressure, which makes caution worthwhile. More broadly, some cannabinoids — notably CBG — act at the α2-adrenoceptor (Cascio 2010), a target linked to blood-pressure regulation. THCV's effects on the heart and circulation remain poorly characterized. Anyone with blood-pressure concerns or on cardiovascular medication should consult a clinician first. Established (Not medical advice.)
Sources
- De Petrocellis 2011 — PMID 21175579 — THCV activity at TRP channels (as extract), in vitro. Grade: Demonstrated.
- Cascio 2010 — PMID 20002104 — CBG acts at the α2-adrenoceptor (and 5-HT1A); cited here only to anchor the cardiovascular/blood-pressure caution. Grade: Demonstrated.
- Chemical identity (Established). THCV: C₁₉H₂₆O₂ · MW ≈286.41 · CAS 31262-37-0 · CID 93147 · the propyl (varin) analog of THC; formed on the varin branch (CBGVA → THCVA → THCV). THC: C₂₁H₃₀O₂ · MW ≈314.46 · CAS 1972-08-3 · intoxicating via CB1 activation.
- Dose-dependent psychoactivity of THCV: reported to block CB1 without intoxicating at low doses and possibly to activate CB1 at higher doses. Described in words only and graded Emerging, with no potency figure and no citation outside the verified anchors.
- Appetite / weight / energy / metabolic benefits: not established in humans, and presented only as third-party claims (catalogue in progress). No dosing is given.
Informational only — not our claims, and not advice. The statements on this page about potential effects, benefits, or uses reflect claims made by third parties (manufacturers, media, traditional use, or preliminary research) and are presented for educational and informational purposes only. CBG Atlas does not make, adopt, endorse, or affirm these claims, and does not represent them as fact. These statements have not been evaluated by the Food and Drug Administration (or any regulator) and are not intended to diagnose, treat, cure, or prevent any disease. Nothing here is medical, legal, or professional advice; cannabinoid effects, safety, and legal status vary by person, product, and jurisdiction and can change over time. Consult a qualified professional before making any health or purchasing decision. Where we can, we show how strong the evidence is and cite the source; where evidence is thin or absent, we say so. Peregrine Biopharma funds the platform and holds no editorial authority.
Report a safety event: if you experienced a possible adverse effect from a cannabinoid product, please report it via the platform's "Report a safety event" path.
Verified sources: De Petrocellis 2011 (PMID 21175579) · Cascio 2010 (PMID 20002104).
Before you act on what you have read
Informational only, not medical advice. CBG Atlas is a scientific reference. Nothing here diagnoses, treats, cures or prevents any disease. Every claim on the page carries the grade of the evidence behind it, and the grade sets the words the claim may use. How we grade evidence.
Each grade rates the support for a claim across the literature. It does not rate any single study. An effect in cells may never show up in people. The grades cover the studies checked up to 9 August 2026. This page is for information and is not medical advice.
Cardiovascular note. CBG is a potent α2-adrenoceptor agonist in vitro, and α2 agonism can lower blood pressure. Anyone taking blood-pressure or other cardiovascular medication should consult a clinician before use. This is educational information, not medical advice.
Funding and independence. Peregrine Biopharma funds the platform and holds no editorial authority.
Report a safety event →Keep exploring
The compounds compared
More comparisons